Verteporfin inhibits papillary thyroid cancer cells proliferation and cell cycle through ERK1/2 signaling pathway

Verteporfin, a FDA approved second-generation photosensitizer, has been demonstrated to have anticancer activity in various tumors, but not including papillary thyroid cancer (PTC). In current pre-clinical pilot study, we investigate the effect of verteporfin on proliferation, apoptosis, cell cycle...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Tian, Wei, Wen-Jun, Wen, Duo, Hu, Jia-Qian, Wang, Yu, Ma, Ben, Cao, Yi-Min, Xiang, Jun, Guan, Qing, Chen, Jia-Ying, Sun, Guo-Hua, Zhu, Yong-Xue, Li, Duan-Shu, Ji, Qing-Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929076/
https://www.ncbi.nlm.nih.gov/pubmed/29721041
http://dx.doi.org/10.7150/jca.21915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929076/
https://www.ncbi.nlm.nih.gov/pubmed/29721041
http://dx.doi.org/10.7150/jca.21915

Ejemplares similares